New
HealthMore in Health →
Biogen reports Phase 2 lupus win as litifilimab improves skin lesions at 24 weeks
Biogen says its anti-BDCA2 antibody litifilimab improved skin lesions after 24 weeks in a Phase 2 lupus study, giving the company a clinical win for a program it hopes will anchor its immunology pipeline.
Key Takeaways
- Biogen says litifilimab improved skin lesions after 24 weeks in a Phase 2 lupus study.
- Endpoints describes the result as a Phase 2 success for an asset Biogen hopes will become central to its immunology pipeline.
DE
DT Editorial AI··via endpoints.news